Latest Medical Technology News

Page 12 of 34
Hydrix Limited reported a 14% revenue decline and a sharp increase in net loss for H1 2026, raising concerns about its financial stability despite securing a major contract.
Ada Torres
Ada Torres
27 Feb 2026
4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.
Ada Torres
Ada Torres
27 Feb 2026
Artrya Limited reported a 44% increase in its half-year loss to $10.7 million as it transitioned from development to commercial operations in the US, securing FDA clearance and signing three foundation customers. An $80 million capital raise underpins its ambitious US expansion and ongoing product development.
Ada Torres
Ada Torres
25 Feb 2026
A recent expert panel convened by Novitas has strongly endorsed Pacific Edge’s urine-based Cxbladder tests for hematuria evaluation, recommending Medicare coverage based on robust clinical evidence and patient care benefits.
Ada Torres
Ada Torres
23 Feb 2026
PolyNovo Limited reported a robust 25.2% increase in half-year revenue to A$75 million, driven by strong U.S. sales and product growth, despite a near break-even net profit impacted by a manufacturing slowdown and a fire at its R&D lab.
Ada Torres
Ada Torres
20 Feb 2026
Cyclopharm Limited is rapidly scaling its US presence for Technegas®, securing new contracts across federal institutions and major health networks in four key regions. The company aims for up to 300 installations by late 2026, boosting recurring revenue streams.
Ada Torres
Ada Torres
19 Feb 2026
BPH Energy Ltd reported a half-year net loss of $925,691, weighed down by investment write-downs and associate losses, while raising $1.2 million to fund exploration and development. The company’s future hinges on a Federal Court review of a critical offshore permit held by investee Advent Energy.
Maxwell Dee
Maxwell Dee
17 Feb 2026
AVITA Medical reported an 11% increase in sales revenue for 2025, driven by deeper market penetration and new product launches, while reducing its net loss by 21%. The company secured a $60 million senior secured credit facility but flagged substantial doubt about its ability to continue as a going concern.
Ada Torres
Ada Torres
13 Feb 2026
Osteopore Limited has secured an exclusive three-year distribution deal with Medprin Biotech GmbH to broaden its presence in Latin America's craniofacial reconstruction market, tapping into a region poised for significant growth.
Ada Torres
Ada Torres
13 Feb 2026
Cyclopharm Limited has completed the initial phase of a $14 million share placement, issuing nearly 9.5 million shares at 95 cents each, with the remaining shares set for issuance later this month.
Ada Torres
Ada Torres
11 Feb 2026
BCAL Diagnostics has launched its Avantect blood tests for pancreatic and ovarian cancer with encouraging early uptake and is advancing its BREASTESTplus breast cancer test towards broader clinical use.
Ada Torres
Ada Torres
5 Feb 2026
Cyclopharm has reported a record $32.3 million in operating revenue for FY2025, led by explosive growth in its U.S. Technegas market following FDA approval. The company reaffirms its ambitious target of 250–300 U.S. installations by mid-2026 amid strong clinical momentum.
Ada Torres
Ada Torres
2 Feb 2026

Browse the archive

Full archive